Myeloproliferative Neoplasms News

Patients with cancer did not have significant reductions in treatment costs or health care use when treated by physicians at accountable care organizations compared to those treated by non-ACOs, according to a study of Medicare claims published in Journal of Clinical Oncology.

A Harvard Medical School project will mine multiple data sources to try to determine why some patients are more likely to have exceptional responses to cancer treatments.

Although adolescents and young adults diagnosed with a hematologic malignancy face similar short- and long-term challenges as children and adults, they may experience unique psychosocial consequences.

The FDA granted the PapGene liquid biopsy test breakthrough device designation for the detection of cancer among people aged older than 65 years, according to the manufacturer.

The FDA issued a warning that azithromycin should not be administered long term to prevent bronchiolitis obliterans syndrome among patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant.

Patients who underwent blood or marrow transplantation during childhood remained at greater risk for death up to 25 years later compared with the general population, according to a study published in JAMA Oncology.

Individuals who received monthly high concentrations of vitamin D without calcium did not appear to have lower risk for cancer, according to findings from a post-hoc analysis of the Vitamin D Assessment study.

The Leukemia & Lymphoma Society appointed five new members to its board of directors and also named its new chief operating officer.

Researchers from the American Cancer Society identified trends in disparities and outcomes for cancer over the last few decades in an effort to highlight the need for better quality care for all individuals with cancer, according to a report published in CA: A Cancer Journal for Clinicians.

A randomized phase 3 trial designed to evaluate luspatercept among patients with myelodysplastic syndrome with chronic anemia met its primary endpoint, according to the agent’s manufacturer.